Donald R VanDevanter1, Nathan J Morris2, Michael W Konstan2. 1. Case Western Reserve University School of Medicine, Cleveland, OH, USA. Electronic address: drv15@case.edu. 2. Case Western Reserve University School of Medicine, Cleveland, OH, USA.
Abstract
BACKGROUND: Single-center analyses have suggested that the number of CF pulmonary exacerbations (PEx) treated with intravenous antibiotics an individual has experienced in the prior year is significantly associated with their future PEx hazard. METHODS: We studied Prior-year PEx association with future PEx hazard by Cox proportional hazards regression among CF Foundation Patient Registry patients who experienced PEx after Jan 1, 2010. RESULTS: Among 13,579 patients, those with 1, 2, 3, or ≥4 Prior-year PEx treated with intravenous antibiotics were at 1.8, 2.9, 4.8, and 8.7 higher PEx hazard vs those without (P<.0001). Adjustment with significant demographic and clinical covariates (univariate P≤.0001) reduced Prior-year PEx hazard ratios to 1.6, 2.4, 3.6, and 6.0 (P<.0001). No other covariates had adjusted hazard ratios of >1.7. CONCLUSIONS: Prior-year PEx strongly associate with future PEx hazard and should be accounted for in prospective trials where treatment-associated change in PEx hazard is an efficacy outcome.
BACKGROUND: Single-center analyses have suggested that the number of CF pulmonary exacerbations (PEx) treated with intravenous antibiotics an individual has experienced in the prior year is significantly associated with their future PEx hazard. METHODS: We studied Prior-year PEx association with future PEx hazard by Cox proportional hazards regression among CF Foundation Patient Registry patients who experienced PEx after Jan 1, 2010. RESULTS: Among 13,579 patients, those with 1, 2, 3, or ≥4 Prior-year PEx treated with intravenous antibiotics were at 1.8, 2.9, 4.8, and 8.7 higher PEx hazard vs those without (P<.0001). Adjustment with significant demographic and clinical covariates (univariate P≤.0001) reduced Prior-year PEx hazard ratios to 1.6, 2.4, 3.6, and 6.0 (P<.0001). No other covariates had adjusted hazard ratios of >1.7. CONCLUSIONS: Prior-year PEx strongly associate with future PEx hazard and should be accounted for in prospective trials where treatment-associated change in PEx hazard is an efficacy outcome.
Authors: Michael W Konstan; Wayne J Morgan; Steven M Butler; David J Pasta; Marcia L Craib; Stefanie J Silva; Dennis C Stokes; Mary Ellen B Wohl; Jeffrey S Wagener; Warren E Regelmann; Charles A Johnson Journal: J Pediatr Date: 2007-06-22 Impact factor: 4.406
Authors: Maria T Britto; Uma R Kotagal; Richard W Hornung; Harry D Atherton; Joel Tsevat; Robert W Wilmott Journal: Chest Date: 2002-01 Impact factor: 9.410
Authors: A L Smith; C Doershuk; D Goldmann; E Gore; B Hilman; M Marks; R Moss; B Ramsey; G Redding; T Rubio; J Williams-Warren; R Wilmott; H D Wilson; R Yogev Journal: J Pediatr Date: 1999-04 Impact factor: 4.406
Authors: Kaïssa de Boer; Katherine L Vandemheen; Elizabeth Tullis; Steve Doucette; Dean Fergusson; Andreas Freitag; Nigel Paterson; Mary Jackson; M Diane Lougheed; Vijay Kumar; Shawn D Aaron Journal: Thorax Date: 2011-06-15 Impact factor: 9.139
Authors: J K Block; K L Vandemheen; E Tullis; D Fergusson; S Doucette; D Haase; Y Berthiaume; N Brown; P Wilcox; P Bye; S Bell; M Noseworthy; L Pedder; A Freitag; N Paterson; S D Aaron Journal: Thorax Date: 2006-07-14 Impact factor: 9.139
Authors: Catherine Ann Byrnes; Suzanna Vidmar; Joyce L Cheney; John B Carlin; David S Armstrong; Peter J Cooper; Keith Grimwood; Marj Moodie; Colin F Robertson; Margaret Rosenfeld; Harm A Tiddens; Claire E Wainwright Journal: Thorax Date: 2013-01-23 Impact factor: 9.139
Authors: Jonathan D Cogen; Kathryn B Whitlock; Ronald L Gibson; Lucas R Hoffman; Donald R VanDevanter Journal: J Cyst Fibros Date: 2019-05-28 Impact factor: 5.482
Authors: Don B Sanders; George M Solomon; Valeria V Beckett; Natalie E West; Cori L Daines; Sonya L Heltshe; Donald R VanDevanter; Jonathan E Spahr; Ronald L Gibson; Jerry A Nick; Bruce C Marshall; Patrick A Flume; Christopher H Goss Journal: J Cyst Fibros Date: 2017-04-29 Impact factor: 5.482
Authors: Susanna A McColley; Michael W Konstan; Bonnie W Ramsey; J Stuart Elborn; Michael P Boyle; Claire E Wainwright; David Waltz; Montserrat Vera-Llonch; Gautham Marigowda; John G Jiang; Jaime L Rubin Journal: J Cyst Fibros Date: 2018-08-23 Impact factor: 5.482
Authors: Kathrin Krause; Benjamin T Kopp; Mia F Tazi; Kyle Caution; Kaitlin Hamilton; Asmaa Badr; Chandra Shrestha; Dmitry Tumin; Don Hayes; Frank Robledo-Avila; Luanne Hall-Stoodley; Brett G Klamer; Xiaoli Zhang; Santiago Partida-Sanchez; Narasimham L Parinandi; Stephen E Kirkby; Duaa Dakhlallah; Karen S McCoy; Estelle Cormet-Boyaka; Amal O Amer Journal: J Cyst Fibros Date: 2017-12-11 Impact factor: 5.482
Authors: Ranjani Somayaji; Renee Russell; Jonathan D Cogen; Cristopher H Goss; Sarah E Nick; Milene T Saavedra; Jennifer L Taylor-Cousar; Jerry A Nick; Dave P Nichols Journal: Ann Am Thorac Soc Date: 2019-07